Adding Pirtobrutinib to R-CHOP for Richter Transformation
July 10, 2026
A large prospective collaborative trial tests whether adding pirtobrutinib to standard R-CHOP improves outcomes in Richter transformation.
A large prospective collaborative trial tests whether adding pirtobrutinib to standard R-CHOP improves outcomes in Richter transformation.
Though it is still early, the combination of pirtobrutinib-venetoclax-obinutuzumab appears to have good efficacy in patients with Richter transformation.
First-line treatment with combination pirtobrutinib, venetoclax, and obinutuzumab produces deep remissions in patients with CLL.
In the first head-to-head comparison, patients with CLL who were treated with either pirtobrutinib or ibrutinib responded equally well to both treatments.
Pirtobrutinib as a first-line therapy significantly improved progression-free survival in patients with CLL / SLL compared with chemoimmunotherapy.
On Dec. 3, 2025 the FDA gave full approval to pirtobrutinib for use in chronic lymphocytic leukemia (CLL) after treatment with a covalent BTK inhibitor.
Pirtobrutinib provides longer progression-free survival and is safer than idelalisib-rituximab and bendamustine-rituximab for treating relapsed CLL.
The first-line combination pirtobrutinib, venetoclax, and obinutuzumab produces deep remissions in the majority of patients with CLL.
The combination of pirtobrutinib, venetoclax, and rituximab was very effective and produced deep remissions in patients with relapsed / refractory CLL.